How to Get a GLP-1 Covered by Insurance (2026 Guide)

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on the 3-month and 6-month plans (full refund on 3- and 6-month plans) · cancel anytime

At a glance: How to Get a GLP-1 Covered by Insurance

Step	What it involves	Why it matters
1. Confirm your benefit	Check your formulary for a weight-management drug benefit	Roughly 40% of employer-sponsored plans exclude weight-loss drugs entirely1
2. Meet the criteria	BMI ≥30, or ≥27 + a comorbidity; document prior lifestyle attempts	Standard prior-auth requirements across major payers
3. Submit a strong PA	Prior-auth form + Letter of Medical Necessity + chart notes, submitted together	Most first-pass denials are documentation gaps, not ineligibility
4. Appeal if denied	Written appeal + peer-to-peer review request	Well-documented appeals frequently succeed; typically resolve in 30–60 days

Coverage rules and formularies change frequently. Verify current requirements with your insurer before submitting a prior authorization.

Step 1: Confirm whether your plan covers weight-loss drugs at all

Before beginning the prior-authorization process, confirm your plan actually includes a weight-management drug benefit. This is the step most people skip — and it can save significant time and effort.

Roughly 40% of employer-sponsored plans in the U.S. exclude weight-loss medications entirely.¹ That exclusion is often a deliberate cost-management decision made by the employer at the plan-design level, not by the insurer itself — which means it may not surface in a standard drug-lookup tool. Call the member services number on your insurance card and ask specifically: "Does my plan include coverage for GLP-1 medications used for weight management, such as Wegovy or Zepbound?"

A few coverage categories worth knowing about:

• Diabetes-labeled GLP-1s (Ozempic, Mounjaro): These molecules are FDA-approved for type 2 diabetes management, and most commercial plans cover them for that indication with standard diabetes prior-auth criteria. If you have type 2 diabetes, coverage is more accessible through this route.
• State and federal employee plans: Some FEHB plans and union contracts cover GLP-1 weight-management medications more broadly than typical commercial plans — check your plan's Summary of Benefits and Coverage.
• Marketplace (ACA) plans: Coverage varies significantly by carrier and plan tier. Check the formulary on healthcare.gov or directly with the insurer's member services line.

If your plan explicitly excludes weight-loss drugs, realistic options include: (1) switching plans at the next open enrollment to one with coverage, (2) requesting an exception through the appeals process (rarely successful for categorical exclusions, but worth attempting if there is a documented comorbidity), or (3) exploring self-pay pathways — including compounded GLP-1 programs, which require no insurance and no prior authorization.

Step 2: Meet — and document — the clinical criteria

When a plan does cover weight-management GLP-1s, it almost always requires prior authorization with specific clinical criteria. The standard threshold across most major payers is:

• BMI ≥30 (meeting the clinical definition of obesity), or
• BMI ≥27 with at least one weight-related comorbidity — typically hypertension, dyslipidemia, prediabetes, type 2 diabetes, established cardiovascular disease, or obstructive sleep apnea

Many plans additionally require 3–6 months of documented diet-and-exercise effort — participation in a structured program, a referral to a registered dietitian, or consistent chart notes from a provider documenting the attempt. A statement that you have "been trying to eat better" is generally not sufficient; you need clinical documentation.

The NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) documents the approved indications for prescription obesity medications and the patient populations studied in clinical trials — the same framework most insurers use as their clinical anchor.²

What to have in place before your provider submits the request:

1. Confirm your current BMI is recorded in your chart with a recent measurement date. If you haven't had an office visit in the past year, schedule one.
2. Ask your provider to document any comorbidities in the chart — as diagnosed conditions with ICD-10 codes, not just as symptoms or patient-reported history.
3. If you have participated in any weight-management program or had nutrition counseling, gather those records. Documented prior attempts in your primary care chart also count.
4. Ask your provider explicitly: "Can you write a Letter of Medical Necessity for this medication?" — it is a separate document from the prior-auth form, and it materially strengthens the submission.

Step 3: Submit a strong prior authorization

This is where approvals are won or lost. The prior-auth process is a documentation review — the insurer's medical team reads the submitted materials and applies their coverage criteria. Getting it right on the first submission significantly reduces back-and-forth that can delay treatment by weeks.

What to include in the submission

1. The insurer's prior-auth form — required; your provider initiates this. Ask whether the insurer accepts electronic submissions through their provider portal, which often speeds up processing.
2. A Letter of Medical Necessity (LMN) — a separate, provider-written letter that goes beyond the PA form. A strong LMN includes:
   • Your diagnosis (e.g., obesity per ICD-10 E66.01, or overweight with hypertension)
   • Your current BMI with a measurement date
   • A summary of prior weight-management attempts and their outcomes
   • The clinical rationale explaining why pharmacological treatment is appropriate at this time
   • The specific drug being requested, with its FDA-approved indication
3. Supporting chart notes — 6–12 months of relevant visits covering weight management, comorbidity management, or nutrition counseling.
4. Relevant clinical guidelines — many providers cite Obesity Medicine Association or ACC/AHA weight-management guidelines when submitting; this anchors the request in established clinical consensus rather than leaving it as a judgment call.

For Cigna, the GLP-1 prior-auth coverage criteria are published in their GLP-1 coverage position criteria document (PDF).³ Most major carriers publish similar documents — reviewing the specific rubric before you submit lets you confirm your documentation matches their criteria exactly.

Formulary placement matters

Some pharmacy benefit managers place Wegovy (semaglutide, FDA-approved for chronic weight management) on a different formulary tier than Zepbound (tirzepatide, FDA-approved for chronic weight management), or vice versa. Requesting the plan's preferred drug reduces the chance of a denial on formulary grounds. Check your drug formulary before specifying a drug in the prior-auth request.

Step 4: Appeal a denial — and request a peer-to-peer review

A denial is not the end of the process. Insurance plans are required by law to maintain an appeals process, and a well-documented appeal frequently succeeds — particularly when the initial denial was based on missing documentation, which is the most common cause.

The two-track appeal process

1. Written appeal: Submit a formal written appeal through the insurer's process — typically within 60–180 days of the denial notice. Include everything from the original submission plus any information the denial letter cited as missing. Reference the specific coverage criteria from the plan document to frame the response in the insurer's own language.
2. Peer-to-peer review: This is the highest-leverage step. Your provider calls the insurer's medical director and makes the clinical case directly. Peer-to-peer reviews are more effective than written appeals alone because they allow real-time clarification. Ask your provider explicitly to request one — not all practices initiate this automatically, and patients who ask for it see markedly better outcomes.

Denials citing "not medically necessary" are among the most appealable because you can counter with published clinical guidelines and patient-specific chart evidence. The FDA's postmarket drug safety resources and the NIDDK clinical treatment standards provide the kind of authoritative sourcing that strengthens an appeal in a way that is difficult for a plan medical reviewer to set aside.⁴

Appeals typically resolve within 30–60 days. If your internal appeal is denied, you generally have the right to an external, independent review — a protection for most employer-sponsored and ACA marketplace plans under federal law.

Keep a paper trail. Document every call with date, time, representative name, and what was discussed. Submit all appeals in writing. Insurers are required to respond in writing with a specific rationale.

Medicare and Medicaid coverage in 2026

Medicare Part D has historically excluded anti-obesity medications — a longstanding gap in federal coverage. That is beginning to change in 2026.

Medicare Bridge program (effective July 2026)

CMS announced a Bridge program beginning July 1, 2026, providing eligible Medicare beneficiaries access to GLP-1 medications at approximately $50/month.⁵ The details on which drugs are included, exact eligibility criteria, and enrollment mechanics are being confirmed on the CMS newsroom page — verify current terms directly before assuming eligibility.

Medicare Part B

Some GLP-1 medications administered in a clinical setting may be covered under Part B rather than Part D, depending on the method of administration and the clinical setting. Ask your provider whether this pathway applies to your specific situation.

Medicaid

Coverage varies significantly by state. As of mid-2026, roughly 13 states cover GLP-1 medications for obesity under Medicaid; the remainder either exclude them categorically or require specific metabolic comorbidities. If you are enrolled in Medicaid, check your state's preferred drug list (PDL) or call the member services line for your specific plan.

When insurance coverage isn't possible: self-pay options

If your plan excludes weight-loss drugs, an appeal is unsuccessful, or you need to begin treatment while a coverage decision is pending, self-pay options exist at a range of price points.

Brand-name self-pay programs

Both Novo Nordisk and Eli Lilly offer direct-pay savings programs:

• Wegovy (semaglutide for obesity): NovoCare has offered a savings program — rates have changed multiple times in 2026, so verify the current price directly at wegovy.com before making a decision.⁶
• Zepbound (tirzepatide for obesity): LillyDirect's self-pay vial program offered tiered pricing by dose (as of early 2026, per LillyDirect) — verify current tiers at LillyDirect before deciding.⁷

Both GoodRx and other prescription-savings platforms also aggregate GLP-1 pricing across pharmacies — a useful cross-check when comparing out-of-pocket costs.⁹ Note that manufacturer savings programs typically cannot be combined with federal health care programs (Medicare, Medicaid, TRICARE).

Compounded GLP-1 programs

Compounded semaglutide and compounded tirzepatide — prepared by state-licensed 503A compounding pharmacies for individual patients under a licensed clinician's prescription — are available through telehealth programs without insurance or prior authorization. These medications are not FDA-approved and not the same as, or therapeutically equivalent to, the brand-name drugs; they are prepared as patient-specific formulations and dispensed only when a licensed provider determines they are clinically appropriate. The FDA's human drug compounding resource explains the regulatory framework.⁸

For a side-by-side breakdown of brand-name, compounded, and insurance-covered cost pathways, see our complete GLP-1 cost guide for 2026, which draws from our open GLP-1 telehealth pricing dataset.

Where Nouri fits if insurance is not an option

Nouri's compounded GLP-1 program requires no insurance and no prior authorization. When prescribed by a U.S.-licensed physician after reviewing your health intake, the program includes compounded semaglutide or compounded tirzepatide — prepared by Jungle Jim's Pharmacy (a state-licensed 503A pharmacy in Fairfield, OH) and VialsRX — plus a personalized nutrition plan, a movement plan, and ongoing clinical support, at one all-in price with no separate membership fee and no per-dose surcharge.

Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, Wegovy, Ozempic, Zepbound, or Mounjaro. Medication is prescribed only if clinically appropriate after review by a licensed provider. Not all applicants qualify.

Current pricing (all-in, no add-ons):

Medication	6-month plan	3-month plan	Monthly (no commitment)
Compounded semaglutide	$120/mo ($720 billed every 6 months)	$145/mo ($435 billed every 3 months)	$175/mo
Compounded tirzepatide	$175/mo ($1,050 billed every 6 months)	$199/mo ($597 billed every 3 months)	$225/mo

Verify current pricing at joinnouri.com/becoming. Longer commitments reduce the monthly cost. Any prescribed dose, same price.

A note on "teaser" pricing in the compounded space: advertised "$99/month" figures elsewhere often add a separate $49–$79 monthly membership fee; compare all-in numbers, not the sticker price.

Nouri is LegitScript-certified. The Nouri Promise: if you are not satisfied in your first 30 days, you receive a full refund — available on the 3-month and 6-month plans.

Related cost guides

• Complete GLP-1 Cost Guide 2026 (pricing pillar)
• Does Insurance Cover Wegovy & Zepbound?
• Can You Use HSA/FSA for a GLP-1?
• Compounded vs. Brand GLP-1 Cost
• Semaglutide Cost With and Without Insurance
• Cheapest Way to Get a GLP-1 (Cost Comparison)

Start your visit with Nouri →
5-minute questionnaire · reviewed by a licensed clinician · cancel anytime

Frequently asked questions

How do I get Wegovy covered by insurance?

Confirm your plan has a weight-management drug benefit, meet the criteria (usually BMI ≥30, or ≥27 with a related condition), and submit a prior authorization with a Letter of Medical Necessity and chart notes. If denied, appeal and request a peer-to-peer review. Coverage is plan-specific — verify your formulary before starting the process.

What BMI do you need for insurance to cover a GLP-1?

Most insurers require BMI ≥30 (the clinical obesity threshold), or BMI ≥27 with at least one weight-related condition — typically hypertension, prediabetes, type 2 diabetes, high cholesterol, cardiovascular disease, or obstructive sleep apnea. Exact criteria vary by plan and are published in each insurer's coverage-policy document.

What is a prior authorization for weight loss meds?

It is the insurer's formal approval process before they will cover the drug. Your provider submits documentation showing you meet the plan's clinical criteria — typically BMI thresholds, a comorbidity, and often prior documented diet-and-exercise attempts. Without prior authorization, the claim is typically rejected at the pharmacy.

How do I appeal a denied GLP-1 insurance claim?

Submit a written appeal with your chart notes and the relevant clinical guidelines, and request a peer-to-peer review where your provider speaks directly with the plan's medical director. Appeals typically resolve in 30–60 days. If the internal appeal is denied, you generally have the right to an external, independent review under federal law.

What is a letter of medical necessity for Wegovy or Zepbound?

It is a letter from your licensed provider documenting your diagnosis (obesity, or overweight with a comorbidity), your BMI, prior weight-loss attempts, and the clinical rationale for the medication. It strengthens both insurance prior authorizations and potential HSA/FSA reimbursement eligibility — though eligibility depends on your plan; confirm with your plan administrator.

Does Medicare cover GLP-1 weight loss drugs in 2026?

Medicare Part D has historically excluded anti-obesity medications. CMS announced a Bridge program beginning July 1, 2026, at approximately $50/month for eligible Medicare beneficiaries. Verify current eligibility criteria and the covered drug list directly on CMS.gov before assuming coverage — details may evolve after launch.

How do I get my doctor to prescribe a GLP-1 for insurance coverage?

Have an open discussion with your provider about your weight history, BMI, and any related health conditions. If a GLP-1 is clinically appropriate, your provider can document the medical necessity and submit the prior authorization. A telehealth provider can complete this process as well — the prior-auth pathway is the same regardless of whether care is in-person or remote.

Sources & references

1. Healthline: Will insurance cover GLP-1 for weight loss (June 2026)
2. NIH NIDDK: Prescription medications to treat overweight and obesity
3. Cigna: GLP-1 prior-auth coverage position criteria (PDF)
4. FDA: Postmarket drug safety information for patients and providers
5. CMS: $50 monthly access to GLP-1 medications for Medicare beneficiaries
6. Wegovy self-pay & savings programs (NovoCare) — verify current rates before deciding
7. Zepbound self-pay vials via LillyDirect — verify current tiers before deciding
8. FDA: Human drug compounding
9. GoodRx: GLP-1 cost and savings guide (June 2026)
10. Nouri program pricing — joinnouri.com/becoming (June 2026)
11. Nouri GLP-1 telehealth pricing dataset 2026 (HuggingFace)

Medically reviewed by Amber Patel, MD. Authored by the Nouri Editorial Team. Nouri content is reviewed by licensed clinicians and updated as coverage policies and clinical guidance change.

Prices and coverage rules described here reflect publicly available information as of June 2026 and change frequently — verify current figures with the manufacturer, your insurer, your pharmacy, and (for HSA/FSA or tax questions) a qualified tax professional before making decisions. This is general information, not medical, financial, insurance, or tax advice. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Compounded medications are prepared as patient-specific formulations and prescribed only when clinically appropriate by a licensed provider. Individual results vary.